Prediction of urinary excretion of technetium-99m-MAG3

被引:0
|
作者
Russell, CD
Dubovsky, EV
Taylor, AT
机构
[1] Univ Alabama Hosp, Birmingham, AL USA
[2] VA Med Ctr, Birmingham, AL USA
[3] Emory Univ Hosp, Atlanta, GA 30322 USA
关键词
technetium-99m-mercaptotriacetylglycine; kidney transplant; kidney function; transplant rejection;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The urinary excretion of Tc-99m-mercaptotriacetylglycine (MAG3), like that of I-131-orthoiodohippurate (OIH), can be used to identify acute renal transplant rejection and measure its severity. This parameter is often quantitated as the excretory index (observed excretion/predicted excretion). A new method for predicting the urinary excretion of Tc-99m-MAG3 is presented. Methods: The expected excretion was calculated from multisample plasma time-activity curves in 122 subjects, with correction for the first pass of the initial bolus. The resulting formula was tested prospectively against actual urine measurements in an additional 466 subjects. Results: Least-squares fitting led to the following equation: Predicted excretion = 0.79(1-exp(-0.0066C(MAG3)), with residual s.d. 0.06, where C-MAG3 is MAG3 clearance in ml/min and the predicted excretion is expressed as a fraction of the administered dose. Tested prospectively in the additional 466 subjects, the s.d, was 0.09, Conclusion: A new formula to predict the urinary excretion of Tc-99m-MAG3 has been developed and prospectively validated. Based on our data, the normal range for the excretory index using MAG3 is the same as that of I-131-OIH, 0,8-1.2.
引用
收藏
页码:1257 / 1259
页数:3
相关论文
共 50 条
  • [31] TECHNETIUM-99M-MAG3 CLEARANCE AS A PARAMETER OF EFFECTIVE RENAL PLASMA-FLOW IN PATIENTS WITH PROTEINURIA AND LOWERED SERUM-ALBUMIN LEVELS
    KENGEN, RA
    MEIJER, S
    BEEKHUIS, H
    PIERS, DA
    JOURNAL OF NUCLEAR MEDICINE, 1991, 32 (09) : 1709 - 1712
  • [32] Technetium-99m-MAG3 renal studies in spinal cord injury patients: Normal range, reproducibility, and change as a function of duration and level of injury
    Klingensmith, WC
    Lammertse, DP
    Briggs, DE
    Smith, WI
    Roberts, JF
    Froelich, JW
    Sutherland, JD
    SPINAL CORD, 1996, 34 (06) : 338 - 345
  • [33] RADIATION EXPOSURE BY TECHNETIUM-99M MAG3 - REPLY
    WOOTEN, WW
    ESHIMA, D
    TAYLOR, A
    JOURNAL OF NUCLEAR MEDICINE, 1989, 30 (05) : 720 - 721
  • [34] Preparation and use of NHS-MAG(3) for technetium-99m labeling of DNA
    Winnard, P
    Chang, F
    Rusckowski, M
    Mardirossian, G
    Hnatowich, DJ
    NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (05) : 425 - 432
  • [35] IMPROVEMENT OF RENAL SCINTIGRAPHY USING 99M-TECHNETIUM MERCAPTOACETYLTRIGLYCINE (MAG3)
    ERPENBACH, K
    EBERT, A
    WIELER, H
    UROLOGE-AUSGABE A, 1991, 30 (02): : 99 - 105
  • [36] Technetium-99m MAG3 renal scintigraphy with demonstration of aortic dissection
    Nguyen, BD
    CLINICAL NUCLEAR MEDICINE, 2005, 30 (08) : 586 - 587
  • [37] FACTORS ALTERING THE HEPATOBILIARY EXCRETION OF TC-99M MAG3
    ESHIMA, D
    SHATTUCK, L
    TAYLOR, A
    GRAHAM, D
    PAYNE, S
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P129 - P129
  • [38] RENAL EXCRETION CHARACTERISTICS OF DERIVATIVES OF TC-99M) MAG3
    VERBRUGGEN, A
    CLEYNHENS, B
    HOOGMARTENS, M
    DEROO, M
    BRITISH JOURNAL OF RADIOLOGY, 1988, 61 (727): : 655 - 655
  • [39] RENAL EXCRETION OF TECHNETIUM-99M DIPHOSPHONATE IN OSTEOMALACIA
    FOGELMAN, I
    BESSENT, RG
    ANNALS OF INTERNAL MEDICINE, 1979, 91 (02) : 320 - 321
  • [40] Technetium-99m antibodies labeled with MAG(3) and SHNH: An in vitro and animal in vivo comparison
    Lei, K
    Rusckowski, M
    Chang, F
    Qu, T
    Mardirossian, G
    Hnatowich, DJ
    NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (07): : 917 - 922